Evidence map›Paper›PMID 41686336›Full record

ArticleThe international journal of cardiovascular imaging2026

Coronary plaque burden assessed by coronary CT angiography in individuals with type 1 diabetes and healthy controls.

Cheyenne Y Y Beverloo, Shirin Ibrahim, Nick S Nurmohamed, Coco M Fuhri Snethlage, Mijra Koning, Andrew J Murphy, Erik H Serné, R Nils Planken, Max Nieuwdorp, Erik S G Stroes and 1 more

Abstract read
In one paragraph

Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cheyenne Y Y Beverloo *Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Shirin Ibrahim *Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Nick S NurmohamedDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Coco M Fuhri SnethlageDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Mijra KoningDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Andrew J MurphyHematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Australia.
Erik H SernéDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
R Nils PlankenDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Max NieuwdorpDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Erik S G StroesDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Nordin M J HanssenDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. n.m.j.hanssen@amsterdamumc.nl.

Funding

Diabetes Fonds 2020.10.002European Atherosclerosis Society 2023European Research Council 101141346Hartstichting 03-007-2023-0068Hartstichting 2021T055ZonMw 09150172210019ZonMw 09150182010020
6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains a prominent cause of death in individuals with type 1 diabetes (T1D). It is unknown whether guideline-recommended initiation of statin therapy at the age of 40 years is adequate for primary prevention of CVD. We evaluated the coronary plaque burden in asymptomatic individuals with T1D compared with healthy controls. Individuals with T1D who used continuous glucose monitoring (CGM) sensors were compared with healthy controls. CGM data from ≥ 1 year prior to enrollment were obtained. All participants underwent coronary computed tomography angiography, which was followed by atherosclerosis imaging-quantitative computed tomography. Fifty-eight individuals with T1D and 45 healthy controls (mean age 42.1 ± 4.9 vs. 41.0 ± 3.5 years) participated. The participants with diabetes had a median disease duration of 24 years [IQR 17, 30]. The prevalence of significant coronary plaque was similar in both groups (31% vs. 22%) (OR 2.71 [95% CI 0.9 to 9.07]), as were plaque volumes and the presence of high-risk plaque, even after adjusting for clinical risk factors. Participants with T1D had a median time in range of 71% [IQR 52, 79] and a mean HbA1c of 55 ± 12 mmol/mol. The CGM metrics (time in range, time above range, time below range and glucose coefficient of variation) were not associated with plaque volumes. Individuals with long-standing well-regulated T1D and on-target lipid levels and blood pressure, exhibited a similar coronary plaque burden compared with healthy controls. These findings support early and aggressive risk factor management in T1D.

Indexed as

Computed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDiabetes Mellitus, Type 1Plaque, AtheroscleroticAdultAsymptomatic DiseasesBiomarkersBlood GlucoseCase-Control StudiesContinuous Glucose MonitoringFemaleGlycated HemoglobinHumansMaleBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanAtherosclerosis imagingCoronary artery diseaseCoronary CT angiographyType 1 diabetes

Identifiers

PMID41686336
PMCPMC13136224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.